HILLEVAX INC (HLVX)

US43157M1027 - Common Stock

1.86  -0.04 (-2.11%)

After market: 1.91 +0.05 (+2.69%)

Fundamental Rating

2

Taking everything into account, HLVX scores 2 out of 10 in our fundamental rating. HLVX was compared to 568 industry peers in the Biotechnology industry. HLVX has a great financial health rating, but its profitability evaluates not so good. HLVX has a expensive valuation and it also scores bad on growth.



0

1. Profitability

1.1 Basic Checks

In the past year HLVX has reported negative net income.
HLVX had a negative operating cash flow in the past year.
In the past 5 years HLVX always reported negative net income.
HLVX had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -68.12%, HLVX is doing worse than 64.42% of the companies in the same industry.
HLVX has a Return On Equity (-81.55%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -68.12%
ROE -81.55%
ROIC N/A
ROA(3y)-55.59%
ROA(5y)-144.15%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

HLVX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

7

2. Health

2.1 Basic Checks

Compared to 1 year ago, HLVX has more shares outstanding
Compared to 1 year ago, HLVX has a worse debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of -2.66, we must say that HLVX is in the distress zone and has some risk of bankruptcy.
HLVX has a Altman-Z score (-2.66) which is comparable to the rest of the industry.
HLVX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.66
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

A Current Ratio of 14.25 indicates that HLVX has no problem at all paying its short term obligations.
HLVX's Current ratio of 14.25 is amongst the best of the industry. HLVX outperforms 89.20% of its industry peers.
HLVX has a Quick Ratio of 14.25. This indicates that HLVX is financially healthy and has no problem in meeting its short term obligations.
HLVX's Quick ratio of 14.25 is amongst the best of the industry. HLVX outperforms 89.20% of its industry peers.
Industry RankSector Rank
Current Ratio 14.25
Quick Ratio 14.25

1

3. Growth

3.1 Past

HLVX shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -9.93%.
EPS 1Y (TTM)-9.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%35.8%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

HLVX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.55% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y11.42%
EPS Next 2Y16.51%
EPS Next 3Y12.67%
EPS Next 5Y11.55%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for HLVX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for HLVX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as HLVX's earnings are expected to grow with 12.67% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.51%
EPS Next 3Y12.67%

0

5. Dividend

5.1 Amount

HLVX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

HILLEVAX INC

NASDAQ:HLVX (12/18/2024, 8:27:36 PM)

After market: 1.91 +0.05 (+2.69%)

1.86

-0.04 (-2.11%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap92.65M
Analysts
Price Target
Short Float %
Short Ratio
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -68.12%
ROE -81.55%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 14.25
Quick Ratio 14.25
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-9.93%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y11.42%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y